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Predominance of mature helper T cells with the Leu-
1 +, 2-, 3+, 4+, 5+ phenotype was confirmed in 22 biopsy 
specimens of mycosis fungoides from 15 patients. Dis-
section of the T helper/inducer cells into phenotypically 
distinct subsets was performed with the use of a new 
monoclonal antibody, anti-Leu-8. One might predict a 
predominance of Leu-8+ in mycosis fungoides, as the 
known ratio of Leu-8+/Leu-8- cells is approximately 70/ 
30 in the peripheral blood. Unexpectedly, a deficiency 
of Leu-8 was demonstrated in 18 of the 22 specimens 
from 13 of 15 patients. This finding could not be attrib-
uted to an artifact of the staining method or to therapy, 
and was present in early- as well as late-stage disease. 
Whether neoplastic cells in mycosis fungoides derive 
from Leu-8-subset ofT cells at risk for malignant trans-
formation, or whether there is antigen loss with malig-
nant transformation remains to be determined. Impli-
cations of our finding with regard to etiopathogenesis 
of mycosis fungoides are discussed. 
Mycosis fungoides (MF) is a lymphoproliferative disorder of 
T ce lls which usually expresses lhe T helper ce ll phenotype. 
Historically, classification of MF a nd ils leukemic variant t he 
Sezary syndrome as cutaneous T-cell lymphoma (CT CL) was 
based on t he demonst ration ofT -ce ll membra ne markers such 
as t h e sheep RB C recepto r, as well as functiona l studies of t he 
atyp ica l cell s [ 1]. The development of monoclonal a ntibodies 
led to a more spec ific technique whereby T cell s could be furth er 
characterized as belonging to t he helper/ induce r (Leu-3+) or 
suppresso r/cytotox ic (Leu-2+) subsets [2]. With t he use of 
monoclona l a ntibodies to T -ce ll subsets, numerous investiga -
to rs have establi shed t he predominantly T helper phenotype of 
t h e cellular infil t rate in MF [3- 7]. The helper T-cell nature of 
t he infiltra ting cells in MF has also been correlated with in 
v itro fun ctiona l studies characteristic of this subset [3,7]. 
At Stanford , immunophenotyping of MF has been performed 
using a panel of monoclonal antibodies as confirmatory support 
fo r t he diagnos is based on cl inica l and routine histo logic data 
(see Table I). Recent ly, new markers such as anti-Leu-8 have 
been described t hat react wit h many, but not all T cell s, 
including T helper ce ll s [8]. Based on t he known ratio of Leu -
8+ / Leu-8- cells (approximately 70/:30) in t he peripheral blood 
a nd lymp h nodes, one migh t expect a Leu-8+ phenotype in the 
majority or cases of MF. initia lly we exami ned a small number 
of biopsy specimens diagnosed hi sto logica lly as MF, which were 
unexpectedly found to be Leu-8- . After adding this marker to 
our MF sc reening panel, we found t hat t he vast majority of MF 
biopsies were Leu -8- . 
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AIDS: acquired immunodefi ciency syndrome 
CT C L: cuta neous T -ce ll lymphoma 
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The present study demonstrates that t he expression of t he 
majority T -cell marker Leu-8 in MF is uncommon a nd suggests 
that MF can a ri se from phenotypically distinct T helper ce ll 
subsets. The implications of t hi s findin g a re discussed. 
MATERIALS AND METHODS 
Fifteen patie nts re fe rred to the Mycos is Fungoides C linic a t Stanford 
for evaluation a nd trea tme nt we re included in this study. The subjects 
were randomly se lected pa tiem s in whom skin biopsies were conseCll-
t ive ly s ta ined with the panel of monoclo nal an tibodies used in this 
study. Twelve pa t ients we re newly diagnosed as hav ing MF a nd 3 
patient s had recurrent disease following treatme nt with eithe r electro n -
bea m radiatio n, top ical mechlo retha mine, or photochemothe ra py with 
8-met hoxyp so ra len a nd long-wa ve untrav iolet A (PUVA) . S imulta ne-
ous biopsies for immunophe notyping from two diffe rent s kin si tes we re 
obta ined in 2 patient s. Seria l biopsies were obta ined in 5 patient s, 1 of 
whom rema ined untrea ted dur ing this t ime. The inte rim trea tme nt 
moda lity in the othe rs included electron -bea m radiation followed by 
adjuvant top ical mechloretha mine (2 patients), elec t ron -bea m and 
hemibody radiation followed by polychemotherapy (1 patien t) , a nd 
PUVA therapy (I patie nt). 
A clinical diagnos is o f MF was confirmed in a ll cases according t o 
esta bli s hed histologic criteria [9[. Histologic features co ns is ted o f a 
li che noid infiltrate o f atypical mononuclear ce ll s exhibiting epide rmo-
tropis m. Most cases de mo nstrated eit he r class ic P a utrier's m ic roab-
scesses of foca l aggregates of atyp ical mono nuclea r ce ll s in the absence 
of spongios is. Individua l ce ll exocytos is a nd a typ ia were seen in 1 
pa ti ent with nodula r aggregates of MF in the de rmis. Defi nitive t rea l -
me nt fo r MF was ins tituted in a ll cases, based o n clinica l-pathologic 
co rrela tion a nd s tage o f disease according to the Stanford staging 
sys tem, desc ribed previously [1 0,11 [ 
Immunohistology 
One or two cuta neous punch or s have biopsies were obta ined from 
each pa tient and placed in re fri gera ted no rma l sa line . Within a few 
hours, represe ntative portions were cryopreserved. They we re subse-
quent.ly sectioned a nd stained with a three-st age monoclona l a nt ibody-
bi otin -avidin immun operox idase technique as described previous ly 
[7 [. The pa nel of mo noclona l a ntibodies employed is li sted in T able I 
along wi t h the ir palt erns ofT-cell reactivity. Since Leu-4 stains vir -
tua lly a ll T cells, t his ma rke r was used t.o de fine t he tota l number ofT 
cells for assessme nt of the proport ion of T cells that express Leu-8. 
Immunohistologic evaluat ion of each biopsy was performed by two of 
us (GSW a nd RAW). Leu-8+ / Leu-4+ ratios were based upon visua l 
estimation of the total number of Leu-8+ or Leu -4+ ce lls in semi -seri a l 
ti ssue sections. Leu-8 staining was not uniformly positive or negative, 
as would be expec ted, because Leu-2 ... ce ll s are usua lly present. t o a 
sma ll degree in t he MF infiltrate, and because some of the Leu-3+ ce lls 
may be infla mmato ry rather than t umo r ce ll s. Limits for t he presence 
or deficiency o f Leu-8 we re therefore caclulated as follows: 
S ince Lc u-8 s tains a n ave rage o f 75 % of Leu-3+ T cells a nd 60 % of 
Leu-2+ T cells [8 ], a nd s ince the maximum proportio n o f Leu-2 ... ce ll s 
in a ny biopsy was 0.3, then t he mean proportion of Leu-8+ T cell s 
predicted from periphera l bl ood data would be 0.7. T a king into accoun t 
a n SE of± I 0°i, in Leu-8 express ion by pe riphe ra l bl ood T ce ll s (Table 
1), the predicted minimum proportion of Leu-8+ T cells would be 0.6. 
On 1 hi s bas is. we have chosen to accept as a no rma l phenoi.vpe a Leu-
8+ / Leu -4 ... ratio of 2:0.5 since this includes a ll cases with a majority of 
Leu-8+ T cell s. We se lected a Leu -8+ / Leu -4 ... ratio of s 0.3 to represent 
a n abnormal phenotype , s ince th is limi t easily excludes a ll cases in 
which th is ratio is 2:0 .5. 
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RESULTS 
Immunohistochemical sta ining of 22 biopsy specimens of MF 
fro m 15 patients was performed. T he neoplast ic infi ltrate in 
each case exp ressed a predominance of the Leu-1 +, z-, 3+, 4+, 
5+ phenotype characteri stic of mature helper T cells. Further 
classification in to t he Leu-8+ and Leu-8- subsets ofT helper 
cells according to stage of di sease is shown in Table II. Contrary 
to what was expected for a majority T -cell marker, a deficiency 
of Leu-8 was found in 18 of 22 spec imens (Fig 1). Biopsies from 
13 of t he 15 patients exhibited a Leu-8+ / Leu- 4 ratio of :s0.3. 
T here was no co rrelat ion between stage of di sease and Leu-8 
defi ciency which was present in limi ted early patch or plaque 
di sease as we ll as in advanced tumor stage disease with nodal 
invo lvement. Two patients wi th stage II di sease had no abnor-
mali ty in terms of Leu-8. 
Concordance of phenotype was examined in t he 7 patients 
who had 2 biopsies. There was concordance of t he Leu-8-
phenotype in t he 2 patients who had 2 skin biopsies performed 
simulta neously. One of the 5 patients who had 2 se rial biopsies 
showed discordance of t he Leu-8 phenotype. A spec imen from 
this patient was Leu-8+ ini t ia lly. Examination of recurrent 
progressive disease followin g electron-beam therapy revealed a 
deficiency of Leu-8. 
TABLE I. M onoclonal antibodies directed against T -cell subsets 
Classification 
PanT cell 
Majority T cell 
Helpe r T cell 
Cytotox ic/suppres-
so r T cell 
Antibodies" T -ce ll reactivi ty 
Anti -Leu- 1,4,5 >N inety- live percent ofT 
cells in blood and lymph 
node 
Anti -Leu-8 Blood: 75 ± 10% of Leu-3+ T 
cells; 60 ± 10% of Leu-2+ 
T ce lls; 70% of tota l T 
cells 
Lymph node: > 90% of tota l 
a nd Leu-3+ T ce lls; > 70% 
of Leu-2+ T ce lls 
Ant i-Leu-3 Blood: - 70% of T cells 
Lymph node: 67- 89 % ofT 
cells 
Anti-Leu-2 Blood:- 30% of T cells 
Lymph node: 15- 31% ofT 
cells 
" All ant ibodies were obta ined from Becton Dickinson, Mounta in 
View, Ca li forni a. 
TABLE II. Leu-8 expression in 22 skin biopsies from 15 patients with 
mycosis fungoides according to stage uf disease 
No. Bx's No. pts with 
Stage' No. pts No. bx's Leu-8 Leu-8 
de fic ient' deficient bx' s 
lA I 2 2 l 
lB 4 5 5 4 
II 7 10 6 5 
Ill :~ 5 5 3 
T ota ls: 15 22 18 T3 
"Stanford staging system 
Stage 1: MF' limi ted to t he skin with no cuta neous tumors or 
ulcers. 
Stage lA: Limited pl aque or eczematous disease with involve-
ment o f less than 10% of the tota l skin su rface. 
Stal{e 18: Ge nera li zed plaque or ecze matous disease with involve-
ment of 10% or greate r of the total skin surface (includes 
erythroderma ). 
Stage I 1: Prese nce of s kin tumors or hi stologica lly documented 
dermatopathic lymphadenopathy. 
Stage III: MF involving t he skin with biopsy-documented in -
volvement of the lymph nodes or spleen. 
Stage IV: Cuta neous a nd extracuta neous MF with docum ented 
viscera l invo lvement.. 
1
' Leu-R defi ciency defined as Leu-8+/Leu-,;· :S 0.3 (see Materials and 
Methods for deta il s ). 
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F IG 1. Leu -8 deficiency in mycos is fun goides, stage lA. Immuno-
peroxidase stain with met hylene blue counterstain . a, F'rozen sections 
of a skin biopsy obtained from a poiki lodermatous patch les ion of MF 
conta in a superficial dermal infiltrate of Leu-4+ T cells wit h epider-
motropism. Stained ce lls ex hibi t a da rk perip hera l rim . X 160. b, Serial 
sect ion from same case showing that lymp hoid ce lls within Pautrier 
microabscesses (large arrowhead) are Leu-8- whi le occasiona l in t rader-
mal lymphocytes are Leu-8+ (small arrowheads). Uniformly da rk 
clumps within the de rmis represent endogenous perox idase activity in 
mast cells and/o r eos inophils (double arrowheads) . x 320. 
DISCUSSION 
Contrary to expected findings with a majority T -cell marker, 
we have shown that Leu-8 expression is uncommon in MF. 
Anti-Leu-8 ident ifies 75 ± 10% of Leu-3+ cells in t he human 
peripheral blood and 60 ± 10% Leu-2+ cells (Table I) [8]. The 
funct ional significance of t he minor Leu-3+8- subset lies in its 
helper effect forB -cell immunoglobulin synthesis, based on the 
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auto logous mixed lymphocyte reaction [8 ]. l t i known that 
both Leu-2+8+ and Leu-2+8- cells a re required for optimal 
suppression of t he helpe r effect [8]. Evaluation of such T-
helpe r sublineages are of particu la r interest in patients wit h 
MF w ho may exhibit immunologic abnormalities such as ele-
vated se rum immunoglobulins [7,12,13]. 
Our findin gs suggest t hat Leu-3+8- T ce lls may be function-
ally hete rogeneous, and t hat in addi t ion to those that help B 
cells, t here may be othe rs whose mai n fu nction is to circul ate 
th rough t he sk in , as in t he skin -associated lymphoid t issue 
(SALT) [14]. Most of our pat ients had no ev idence of hyper-
gammaglobulinemia on routine screening tests. Alternatively, 
phenotype may not co rrelate wit h funct ion in t hese neop last ic 
ce lls which may have lost t heir functiona l abili ty to help B 
ce lls. 
There is su ffi cient ev idence to support t hat t he Leu -8 nega-
tivity is not an a rt ifact of t he sta ining method. S imila r results 
were obta ined when t he staining tec hnique was repeated one 
o r more t imes in seve ra l individua l specimens. Resu lts were 
generally reproducible in addi t iona l specimens from t he same 
patient. Furthermore, most biopsy specimens showed at least 
rare Leu-8+ cell s, and some specimens revealed a majority of 
Leu-8+ cells. Leu-8 negativ ity was not secondary to a ny one 
fo rm of therapy, as most patients were new ly diagnosed as MF 
and had not received spec ific t herapy at t he time t he ir skin 
biopsies were performed. In 4 patients with se ri a l biopsies 
follow ing spec ific therapy, there was no correlation between 
the phenotype and t he interim t reatment modality. 
Leu-8 negativity as demonstrated in our cases of MF may 
have implications with regard to etiopathogenesis of t he dis-
ease. Our findi ngs might indirectly suggest clonali ty in the 
same way heavy- or li ght -chain restriction is used to imply 
clonali ty forB -ce ll lymphomas [15]. In cont rast, in a reactive 
p rocess, a mixture of Leu-8- a nd Leu-8+ T cells would be 
expected, as approximately 70% of T cells in the blood and 
ly mph nodes a re Leu-8+. Whether the neoplastic cells in MF 
derive from a Leu-8- subset ofT ce lls at high r isk for malignant 
t ransformation, or whether t here is loss of t he antigen wit h 
maligna nt transformation remains to be dete rmined. If antigen 
loss occurs, we have shown this to be a n early event, as Leu-8 
deficiency was demonstrated ove r a broad spectrum of clin ical 
stages from li mited patch or plaque stage Ia to tumor stage 
with nodal involve ment (stage II I). 
The minority (:;::;33% ) Leu-8+ cells prese nt in Leu-8-deficient 
skin infil t rates may represent Leu-8 exp ression by normal host 
cells including T cells (Leu-2+ a nd/o r Leu-3+), B cell s, a nd 
granulocytes, since t he majority of each of t hese ce ll types is 
known to be Leu-8+ in t he periphera l blood (16]. It is evident 
from previous studies that host response often comprises a 
s ignificant amount of t he cell infi lt rate in lymphoma [7 ,15]. 
Alternative ly, there may be so me variable a ntige n expression 
by t he tumor cells. If t his occurs, it is not a uni fo rm featu re of 
MF since some cases were essentia lly Leu-8- or Leu-8+, sug-
gesting t hat MF may arise from phenotypica lly distinct T-
helper subsets. 
In addition to MF, t he acquired immunodefi ciency syndrome 
(AIDS) and related condit ions [16,1 7] are the only other re-
ported instances in which there is a defic iency of Leu-8. In 
these immunodeficiencies, t he decrease in Leu- 3+8+ cell s is 
thought to be due to a n actual loss of t hese cells (total Leu -3+ 
ce lls are decreased a nd Leu-3+8- are unchanged [1 6]. In con-
t ras t, in MF one would expect a n increase in total Leu-3+ ce lls 
suggesting eit her t hat Leu-8 is lost from Leu-3+8+ cell s or t hat 
the Leu-3+8- cell s proli ferate. Inte restingly, HTL V retroviruses 
wh ich are cytotox ic a nd cytopathic for helper T cells have bee n 
associated not only wi t h AIDS [18 ,19] but a lso wit h helper T-
cell lymphomas such as adult T -ce ll leukemia/lymphoma 
(ATL) in which some patients have MF- like skin lesions 120, 
21]. It is poss ible that spec ific subtypes of HTLV infection may 
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cause specific a lte ratio ns in t he Leu-8+ / Leu-8- helper T -cell 
ratio. 
It will be important to look at other majority T -cell markers 
in MF. Prio r reports document heterogeneity regarding 
Leu -9 expression in MF [6,7 ], as well as in non-MF CTCL 
[22]. These markers, a lone or in combination, may be useful in 
t he diagnos is of MF in cases of pa rapsoriasis, po ik iloderma, 
erythroderma, fo llicula r mucinosis, other MF -associated erup-
t ions, or in the diagnos is of MF at a n earlier stage t ha n is now 
possible. Future studies include t he effects of microenviron-
ment in the blood a nd lymph nodes on Leu-8 expression. It will 
be important to study Leu-8 exp ression in ben ign sk in T -cell 
in fi ltrates in o rde r to correlate funct ion with phenotype and to 
determine t he feasibi li ty of diagnosing M F, based upon immu-
nophenotypic cri teria. 
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